ClinConnect ClinConnect Logo
Search / Trial NCT04419896

The Informed Genetics Annotated Patient Registry

Launched by MEDNEON · Jun 3, 2020

Trial Information

Current as of July 01, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

Interest and knowledge about the genetics and biology of an individual's inherited risk of disease and progression of disease is growing. Physicians are increasing using tests and technology, including Germline Genetic, Genomic, and Biomarker Testing, to provide insight into a healthy individual's risk and an affected individual's disease characteristics, in order to provide individualized clinical treatments. However, many barriers to widespread and appropriate Germline Genetic, Genomic, and Biomarker Testing persist due to complex guidelines for use, varied quality and cost, rapid advance...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria for Retrospective Subjects:
  • Men and women 18 years or older;
  • Is or was a patient of a Participating Practice and was previously tested with Germline, Genomic, or other Biomarker Tests; and
  • For Germline Genetic Test patients, have a diagnosis of cancer or pathogenic or likely pathogenic (P/LP) result.
  • Inclusion Criteria for Prospective Subjects:
  • Men and women aged 18 years or older;
  • Presents consecutively to a Participating Practice and who has previously been screened and tested (i.e., is a new patient scheduled for a visit at a Participating Practice or is an existing patient who returns to a Participating Practice);
  • Receives or has received Germline, Genomic, or other Biomarker Testing, either through a prior healthcare provider or a Participating Practice; and
  • Consents to be a part of the Registry.

About Medneon

Medneon is a forward-thinking clinical trial sponsor dedicated to advancing innovative therapies through rigorous research and development. Focusing on pediatric and rare diseases, Medneon leverages cutting-edge technology and a patient-centered approach to enhance trial design and execution. With a commitment to collaboration and ethical standards, the company aims to bridge the gap between scientific discovery and clinical application, ensuring that emerging treatments are safe, effective, and accessible for the populations that need them most.

Locations

Redding, California, United States

Nashville, Tennessee, United States

Troy, Michigan, United States

Barrington, Illinois, United States

Dallas, Texas, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials